Select which category you are interested in:
Almac Group launch a Next Generation Sequencing (NGS) service
Pharmatimes have reported that the Northern Ireland based Almac Group is introducing a Next Generation Sequencing (NGS) service to expand its solutions supporting the development of personalised medicine.
Almac has said that the service will support Almac’s biopharmaceutical partners in developing molecular tests for enriching clinical trials and establishing companion diagnostics, with a specific focus on targeted re-sequencing,
Professor Paul Harkin, president and md of Almac’s Diagnostics business unit and Professor of Molecular Oncology at Queen’s University Belfast said “There are only a limited number of platforms that are truly amenable to diagnostic delivery. The NGS field has now moved to a point where it is a viable delivery platform and as such is a logical addition to our suite of services”